Psoriasis | China In-Depth | China | 2020
Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2019-2029 forecast period, fueled by increasing disease prevalence and the launch and growing uptake of targeted agents. Benvitimod, a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), is the most notable of these agents, approved by the NMPA for mild to moderate plaque psoriasis in 2019. However, despite recently launched therapies and emerging therapies set to launch in the coming years, a high unmet need for targeted agents will remain. Additionally, with the ongoing reforms in the regulatory and access and reimbursement landscape of China, multinational companies are likely to be increasingly incentivized to enter the Chinese psoriasis market.
- How large is China’s drug-treatable psoriasis population, and how will drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s psoriasis market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the psoriasis pipeline in China? What sales/uptake could they secure in psoriasis?
- What are the key drivers and constraints in the Chinese psoriasis market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
RELEASE DATE
May 2020
GEOGRAPHY
China
PRIMARY RESEARCH
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists. Supported by survey data collected for this and other DRG research.
EPIDEMIOLOGY
Diagnosed prevalence of psoriasis in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
FORECAST
Ten-year, annualized, drug-level sales and patient shares of key psoriasis therapies through 2029, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 5+ agents; Phase II: 7+ agents; coverage of select early-phase products.
